Cochrane · systematic review · CD007745
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection
Henriquez‐Camacho, C, Gotuzzo, E, Echevarria, J, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table 1
Population: patients with treating strongyloides infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cure overall negative parasitological test | RR 1.79 [1.55, 2.08] | 4 studies · 478 participants | Moderate Downgraded: risk of bias |
Adverse events report of adverse events | RR 0.8 [0.59, 1.09] | 4 studies · 518 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table 2
Population: patients with treating strongyloides infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cure overall negative parasitological test | RR 1.07 [0.96, 1.2] | 3 studies · 467 participants | Low Downgraded: risk of bias |
Adverse events report of adverse events | RR 0.31 [0.2, 0.5] | 3 studies · 507 participants | Moderate Downgraded: risk of bias |